Neoadjuvant targeted treatment (BRAF/MEK inhibition) vs no neoadjuvant treatment
Adverse events, · stage III and IV cutaneous melanoma
1 finding from 1 review
- Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes onlyno estimate extracted1 study · 14 participantsLow